G. Francini

发表

Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer.

G. Francini, L. Paolelli, E. Francini, 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids

G. Francini, E. Francini, R. Petrioli, 2006, British Journal of Cancer.

Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.

G. Francini, R. Petrioli, R. Nuti, 2007, Bone.

[Therapeutic effect of synthetic calcitonin from salmon in Paget's disease and in osteoporosis].

G. Francini, C. Gennari, A. Vattimo, 1977, La Clinica terapeutica.

Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer.

G. Francini, L. Paolelli, E. Francini, 2007, Urology.

Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased raf-1 ubiquitin-dependent degradation

M. Marra, A. Abbruzzese, M. Caraglia, 2005, Cancer biology & therapy.

Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials.

R. Labianca, D. Sargent, R. Goldberg, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients.

G. Francini, L. Paolelli, A. Pascucci, 2006, Oncology reports.

The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.

G. Francini, E. Francini, A. Pascucci, 2008, Cancer treatment reviews.

Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

J. Bonneterre, L. Mauriac, D. Campos, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin

Marco Lorenzi, G. Francini, E. Francini, 2007, Cancer Chemotherapy and Pharmacology.

Reply: UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer

G. Francini, R. Petrioli, 2004, British Journal of Cancer.

Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy

G. Francini, L. Paolelli, E. Francini, 2007, Anti-cancer drugs.

FOLFOX-4 Stop and Go and Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer

Marco Lorenzi, F. Roviello, C. Intrivici, 2007, Oncology.

Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin

C. Bellan, S. Lazzi, G. Francini, 2010, Anti-cancer drugs.

Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine

P. Tagliaferri, M. Caraglia, G. Francini, 2009, Cancer biology & therapy.

Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial)

P. Tassone, P. Tagliaferri, A. Fioravanti, 2008, Clinical Cancer Research.

Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer

M. Caraglia, F. Fulfaro, N. Gebbia, 2005, Cancer Chemotherapy and Pharmacology.

Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients.

M. Sabatino, F. Roviello, G. Francini, 2003, European journal of cancer.

A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2

M. Sabatino, G. Francini, R. Petrioli, 2001, British Journal of Cancer.

GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up

P. Tassone, P. Tagliaferri, M. Caraglia, 2019, Front. Oncol..

Regulatory (FoxP3+) T-cell Tumor Infiltration Is a Favorable Prognostic Factor in Advanced Colon Cancer Patients Undergoing Chemo or Chemoimmunotherapy

P. Tassone, P. Tagliaferri, G. Francini, 2010, Journal of immunotherapy.

Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.

C. Intrivici, E. Bonmassar, A. Aquino, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C

G. Francini, R. Petrioli, S. Gonnelli, 2004, Cancer Chemotherapy and Pharmacology.

A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid

M. Sabatino, G. Francini, R. Petrioli, 2003, British Journal of Cancer.

Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab in advanced non-small-cell-lung cancer patients

S. F. Carbone, P. Tassone, A. Abbruzzese, 2010, Cancer biology & therapy.

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

F. Cappuzzo, L. Livi, D. Galetta, 2018, British Journal of Cancer.

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.

R. Labianca, D. Sargent, R. Goldberg, 2001, The New England journal of medicine.

In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse

P. Opolon, F. Lemonnier, R. Glück, 2003, British Journal of Cancer.

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

S. Cha, R. Labianca, D. Sargent, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of salmon calcitonin in postmenopausal osteoporosis: A controlled double-blind clinical study

M. Passeri, G. Francini, S. Gonnelli, 2007, Calcified Tissue International.

Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes.

M. Sabatino, G. Francini, R. Petrioli, 2001, European journal of cancer.

Hypercalcemia in breast cancer

G. Francini, R. Petrioli, S. Gonnelli, 1993, Clinical & Experimental Metastasis.

Treatment of bone metastases with dichloromethylene bisphosphonate.

G. Francini, R. Petrioli, S. Gonnelli, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum Osteocalcin Concentration in Patients with Prostatic Cancer

G. Francini, C. Gennari, S. Bigazzi, 1988, American journal of clinical oncology.

Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.

G. Francini, R. Petrioli, S. Gonnelli, 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Salmon calcitonin and cGMP production by human kidney: Studies in vivo and in vitro

M. Brandi, G. Francini, C. Rotella, 1983, Calcified Tissue International.

Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens.

L. Voltolini, M. Sabatino, G. Francini, 2003, Lung cancer.

Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation

L. Voltolini, C. Intrivici, M. D. Vecchio, 2007, British Journal of Cancer.

In Vitro Generation of Cytotoxic T Lymphocytes Against HLA-A2.1 -Restricted Peptides Derived from Human Thymidylate Synthase

M. Sabatino, A. Aquino, G. Francini, 2001, Journal of chemotherapy.

Gemcitabine (GEM), 5-Fluorouracil (5-FU) and Folinic Acid (FA) in Patients with Different Gastroenteric Malignancies

M. Clerici, G. Francini, R. Petrioli, 2004, Journal of chemotherapy.

Early magnesium modiﬁcations as a surrogate marker of efﬁcacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients

B. Vincenzi, G. Tonini, R. Addeo, 2011 .

Treatment of an atypical metastatic meningioma: a case report

M. Mazzei, C. Miracco, G. Francini, 2013 .

Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer.

F. Roviello, D. Marrelli, G. Francini, 2020, Surgical oncology.

Weekly high‐dose calcitriol and docetaxel in patients with metastatic hormone‐refractory prostate cancer previously exposed to docetaxel

G. Francini, E. Francini, A. Pascucci, 2007, BJU international.

Sjögren's syndrome and aromatase inhibitors treatment: is there a link?

A. Fioravanti, G. Francini, M. Galeazzi, 2013, Clinical and experimental rheumatology.

Seasonal variation in urinary excretion of cyclic AMP in healthy people

G. Francini, C. Gennari, M. Galli, 1981, Journal of endocrinological investigation.

Hypercalcemia and urinary excretion of cyclic AMP in bronchogenic carcinoma

G. Francini, M. Galli, 1977, World Journal of Surgery.

Circulating Levels of Immunoreactive Peptides and Steroid Hormones in Bronchogenic Carcinoma

G. Francini, S. Gonnelli, B. Lucani, 1986, The International journal of biological markers.

Urinary excretion of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in malignancy.

G. Francini, C. Gennari, M. Galli, 1978, Journal of clinical pathology.

Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.

B. Vincenzi, D. Santini, G. Tonini, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Hepatoid Gastric Carcinoma. A Case Report

T. Megha, C. Vindigni, G. Francini, 1996, International Journal of Biological Markers.

Comparison between CEA, TPA, CA 15/3 and Hydroxyproline, Alkaline Phosphatase, Whole Body Retention of 99mTc MDP in the follow-up of Bone Metastases in Breast Cancer

Leone, G. Francini, R. Petrioli, 1990, The International journal of biological markers.

Histopathological and Prognostic Evaluation of Immunohistochemical Findings in Colorectal Cancer

Marco Lorenzi, C. Minacci, C. Vindigni, 1997, The International journal of biological markers.

Treatment of colon and breast carcinoma cells with 5‐fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA‐A(*)02.01 restricted, CEA‐peptide‐specific cytotoxic T cells in vitro

E. Bonmassar, A. Aquino, G. Francini, 2003, International journal of cancer.

A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer.

A. Piga, S. Cascinu, R. Cellerino, 1996, British Journal of Cancer.

Weekly epirubicin in patients with hormone-resistant prostate cancer

M. Sabatino, G. Francini, A. Manganelli, 2002, British Journal of Cancer.

Influence of intravenous β-adrenergic blockade with or without partial agonist activity upon plasma cyclic AMP and catecholamines in healthy subjects

P. Verdecchia, G. Francini, C. Gennari, 2004, European Journal of Clinical Pharmacology.

Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer.

Marco Lorenzi, G. Francini, R. Petrioli, 1994, Gastroenterology.

The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study

S. Alberts, S. Lazzi, F. Ou, 2020, Translational oncology.

CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

G. Francini, E. Francini, A. Pascucci, 2012, Cancer investigation.

Adjuvant Epirubicin With or Without Ifosfamide for Adult Soft-Tissue Sarcoma

L. Pirtoli, L. Grimaldi, G. Francini, 2002, American journal of clinical oncology.

A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma

A. Abbruzzese, M. Caraglia, G. Francini, 2004, British Journal of Cancer.

Weekly chemotherapy in advanced prostatic cancer.

S. Mondillo, M. Cintorino, G. Francini, 1993, British Journal of Cancer.

Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.

R. Labianca, D. Sargent, M. Buyse, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly Low-Dose Docetaxel in Advanced Hormone-Resistant Prostate Cancer Patients Previously Exposed to Chemotherapy

M. Sabatino, G. Francini, A. Manganelli, 2003, Oncology.

Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.

M. Sabatino, S. Rossi, G. Francini, 2004, Urology.

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study

G. Francini, E. Francini, A. Pascucci, 2011, British Journal of Cancer.

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Daniel J Sargent, Daniel G Haller, Marc Buyse, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study.

P. Sismondi, P. Zola, F. Boccardo, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer.

G. Francini, L. Paolelli, E. Francini, 2020, Journal of geriatric oncology.

Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy

C. Higano, A. Bryce, J. García-Foncillas, 2021, JAMA network open.

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

F. Cappuzzo, L. Livi, D. Galetta, 2018, British Journal of Cancer.

Extramammary invasive Paget’s disease and apocrine angiomatous hamartoma: an unusual association

C. Miracco, G. Francini, E. Francini, 2018, European Journal of Dermatology.

Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2

G. Francini, E. Francini, A. Fiaschi, 2020, Medical Hypotheses.

5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.

F. Lemonnier, R. Urso, E. Bonmassar, 2005, Journal of the National Cancer Institute.

Pharmacokinetics of intraarterial mitomycin C in hypoxic hepatic infusion with embolization in the treatment of liver metastases.

F. Roviello, D. Marrelli, G. Francini, 2002, Vascular pharmacology.

Immune-Reconstituted Influenza Virosome Containing CD40L Gene Enhances the Immunological and Protective Activity of a Carcinoembryonic Antigen Anticancer Vaccine

F. Fallarino, C. Moser, G. Francini, 2005, The Journal of Immunology.

Vaccine Carcinoembryonic Antigen Anticancer Immunological and Protective Activity of a Gene Enhances the CD 40 L Containing Immune-Reconstituted Influenza Virosome

Correale, Concetta, F. Fallarino, 2005 .

Comparison between a cisplatin‐containing regimen and a carboplatin‐containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study

S. Mondillo, G. Francini, A. Manganelli, 1996, Cancer.

Occurrence of Autoimmunity in a Long-Term Survivor with Metastatic Colon Carcinoma Treated with a New Chemo-Immunotherapy Regimen

C. Miracco, A. Fioravanti, G. Francini, 2008, Journal of chemotherapy.

Chemotherapeutic Drugs may be Used to Enhance the Killing Efficacy of Human Tumor Antigen Peptide-specific CTLs

G. Francini, P. Correale, C. Terrosi, 2008, Journal of immunotherapy.

Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience

E. Bonmassar, A. Aquino, G. Francini, 2006, Investigational New Drugs.

High-Affinity HLA-A(*)02.01 Peptides from Parathyroid Hormone-Related Protein Generate In Vitro and In Vivo Antitumor CTL Response Without Autoimmune Side Effects1

M. Sabatino, F. Lemonnier, G. Francini, 2002, The Journal of Immunology.

Effects CTL Response Without Autoimmune Side Generate In Vitro and In Vivo Antitumor Parathyroid Hormone-Related Protein High-Affinity HLA-A ( * ) 02 . 01 Peptides from Pierpaolo Correale

M. Sabatino, F. Lemonnier, G. Francini, 2002 .

Dendritic Cell-Mediated Cross-Presentation of Antigens Derived from Colon Carcinoma Cells Exposed to a Highly Cytotoxic Multidrug Regimen with Gemcitabine, Oxaliplatin, 5-Fluorouracil, and Leucovorin, Elicits a Powerful Human Antigen-Specific CTL Response with Antitumor Activity in Vitro1

M. Caraglia, E. Bonmassar, A. Aquino, 2005, The Journal of Immunology.

Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial.

S. Sestini, M. Sabatino, G. Francini, 2001, European journal of cancer.

[Therapy with bromocriptine and behavior of various hormones in psoriasis patients].

M. Fimiani, L. Andreassi, G. Francini, 1984, Bollettino della Societa italiana di biologia sperimentale.

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Daniel J Sargent, Greg Yothers, Daniel G Haller, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens

M. Sabatino, G. Francini, R. Petrioli, 2002, Cancer Chemotherapy and Pharmacology.

Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma

S. Rossi, G. Francini, A. Manganelli, 2001, Cancer.

A systematic review of FOLFOXIRI chemotherapy for the first‐line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity

G. Fiorentini, G. Turrisi, G. Francini, 2011, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors

Marco Lorenzi, F. Roviello, G. Francini, 2008, Anti-cancer drugs.

Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study

M. Mazzei, G. Francini, E. Francini, 2019, Anti-cancer drugs.

Biweekly Triple Combination Chemotherapy with Gemcitabine, Oxaliplatin, Levofolinic Acid and 5-Fluorouracil (GOLF) Is a Safe and Active Treatment for Patients with Inoperable Pancreatic Cancer

G. Francini, A. Pascucci, R. Petrioli, 2008, Journal of chemotherapy.

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.

R. Labianca, D. Kerr, D. Sargent, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acute effects of salmon, human and porcine calcitonin on plasma calcium and cyclic AMP levels in man

G. Francini, S. Gonnelli, C. Gennari, 1981 .

A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient.

G. Francini, E. Francini, R. Petrioli, 2020, Future oncology.